PerioMonitor™ uses a simple oral rinse and a colourimetric strip to detect neutrophil enzyme activity in saliva—providing a semi-quantitative visual indication of the patient’s inflammatory status in just 60 seconds. The test identifies one of four inflammation levels (Negative, Low, Medium or High), offering an immediate snapshot of oral health that is both clinically useful and easy for patients to understand.

The technology is backed by over 30 peer-reviewed studies and has been clinically validated in multi-centre trials involving more than 500 patients. Research confirms that elevated oral neutrophil levels are closely associated with periodontal disease activity, making PerioMonitor™ a powerful tool for early detection, treatment monitoring, and ongoing risk assessment.

By turning the invisible burden of oral inflammation into visible, measurable data, PerioMonitor™ enhances communication between dental professional and patient. The test fits seamlessly into existing clinical workflows, taking less than five minutes to administer, with no special training or equipment required. It supports personalised, evidence-based care and helps to improve patient engagement and treatment acceptance.

Dental professionals are invited to visit Stand D70 at BDA Birmingham 2025 for live demonstrations and to learn how this breakthrough diagnostic can support clinical decision-making, enhance diagnostic confidence, and elevate standards of care.